HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats

Neuroscience

Volumn 291, Issue , 2015, Pages 53-69

  Shi, Q J ^a,b   Wang, H ^c   Liu, Z X ^a   Fang, S H ^a   Song, X M ^b   Lu, Y B ^a   Zhang, W P ^a   Sa, X Y ^b   Ying, H Z ^b   Wei, E Q ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c Tongde Hospital of Zhejiang Province   (China)

Author keywords

Antagonist; Cerebral ischemia; Cysteinyl leukotriene receptor 2 (CysLT2R); HAMI 3379; Inflammation; Microglia

Indexed keywords

3 [[(3 CARBOXYCYCLOHEXYL)AMINO]CARBONYL] 4 [3 [4 [4 (CYCLOHEXYLOXY)BUTOXY]PHENYL]PROPOXY]BENZOIC ACID; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MESSENGER RNA; PEPTIDOLEUKOTRIENE 2 RECEPTOR; PRANLUKAST; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 3-(((3-CARBOXYCYCLOHEXYL)AMINO)CARBONYL)-4-(3-(4-(4-(CYCLOHEXYLOXY)BUTOXY)PHENYL)PROPOXY)BENZOIC ACID; CHROMONE DERIVATIVE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; CYSTEINYL LEUKOTRIENE RECEPTOR 2; LEUKOTRIENE D4 RECEPTOR; NEUROPROTECTIVE AGENT; PHTHALIC ACID DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PROTECTION; BRAIN TISSUE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HISTOPATHOLOGY; LEUKOCYTE FUNCTION AND CHARACTERISTICS; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEURITIS; NEUROLOGIC DISEASE; NEUTROPHIL ACCUMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SYNTHESIS INHIBITION; RAT; RNA INTERFERENCE; ACUTE DISEASE; ANIMAL; BRAIN; CEREBRAL ARTERY DISEASE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; STROKE; TIME;

ACUTE DISEASE; ANIMALS; BRAIN; BRAIN EDEMA; BRAIN ISCHEMIA; CHROMONES; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INFARCTION, MIDDLE CEREBRAL ARTERY; LEUKOTRIENE ANTAGONISTS; MALE; MICROGLIA; NEUROPROTECTIVE AGENTS; PHTHALIC ACIDS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LEUKOTRIENE; RNA INTERFERENCE; RNA, SMALL INTERFERING; STROKE; TIME FACTORS;

EID: 84923264722     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.02.002     Document Type: Article

References (58)

1. Arumugam T.V., Granger D.N., Mattson M.P. Stroke and T-cells. Neuromolecular Med 2005, 7:229-242.
2. Back M., Dahlen S.E., Drazen J.M., Evans J.F., Serhan C.N., Shimizu T., Yokomizo T., Rovati G.E. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 2011, 63:539-584.
3. Beller T.C., Maekawa A., Friend D.S., Austen K.F., Kanaoka Y. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004, 279:46129-46134.
4. Brait V.H., Arumugam T.V., Drummond G.R., Sobey C.G. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab 2012, 32:598-611.
5. Chu L.S., Wei E.Q., Yu G.L., Fang S.H., Zhou Y., Wang M.L., Zhang W.P. Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice. Acta Pharmacol Sin 2006, 27:282-288.
6. Ciana P., Fumagalli M., Trincavelli M.L., Verderio C., Rosa P., Lecca D., Ferrario S., Parravicini C., Capra V., Gelosa P., Guerrini U., Belcredito S., Cimino M., Sironi L., Tremoli E., Rovati G.E., Martini C., Abbracchio M.P. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006, 25:4615-4627.
7. Clausen B.H., Lambertsen K.L., Babcock A.A., Holm T.H., Dagnaes-Hansen F., Finsen B. Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation 2008, 5:46.
8. Fang S.H., Wei E.Q., Zhou Y., Wang M.L., Zhang W.P., Yu G.L., Chu L.S., Chen Z. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 2006, 140:969-979.
9. Fang S.H., Zhou Y., Chu L.S., Zhang W.P., Wang M.L., Yu G.L., Peng F., Wei E.Q. Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia. Neurosci Lett 2007, 412:78-83.
10. Galea J., Brough D. The role of inflammation and interleukin-1 in acute cerebrovascular disease. J Inflamm Res 2013, 6:121-128.
11. Hu H., Chen G., Zhang J.M., Zhang W.P., Zhang L., Ge Q.F., Yao H.T., Ding W., Chen Z., Wei E.Q. Distribution of cysteinyl leukotriene receptor 2 in human traumatic brain injury and brain tumors. Acta Pharmacol Sin 2005, 26:685-690.
12. Huang X.J., Zhang W.P., Li C.T., Shi W.Z., Fang S.H., Lu Y.B., Chen Z., Wei E.Q. Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation. Glia 2008, 56:27-37.
13. Huang X.Q., Zhang X.Y., Wang X.R., Yu S.Y., Fang S.H., Lu Y.B., Zhang W.P., Wei E.Q. Transforming growth factor beta 1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1. J Neuroinflammation 2012, 9:145.
14. Hui Y., Cheng Y., Smalera I., Jian W., Goldhahn L., Fitzgerald G.A., Funk C.D. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 2004, 110:3360-3366.
15. Ji X., Trandafir C.C., Wang A., Kurahashi K. Effects of the experimental subarachnoid hemorrhage on the eicosanoid receptors in nicotine-induced contraction of the rat basilar artery. J Stroke Cerebrovasc Dis 2012.
16. Jiang W., Hall S.R., Moos M.P., Cao R.Y., Ishii S., Ogunyankin K.O., Melo L.G., Funk C.D. Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol 2008, 172:592-602.
17. Jin R., Liu L., Zhang S., Nanda A., Li G. Role of inflammation and its mediators in acute ischemic stroke. J Cardiovasc Transl Res 2013, 6:834-851.
18. Kanaoka Y., Maekawa A., Austen K.F. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 2013, 288:10967-10972.
19. Lakhan S.E., Kirchgessner A., Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009, 7:97.
20. Lambertsen K.L., Biber K., Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 2012, 32:1677-1698.
21. Lin T.N., He Y.Y., Wu G., Khan M., Hsu C.Y. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993, 24:117-121.
22. Liu S., Agalliu D., Yu C., Fisher M. The role of pericytes in blood-brain barrier function and stroke. Curr Pharm Des 2012, 18:3653-3662.
23. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
24. Maekawa A., Kanaoka Y., Xing W., Austen K.F. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 2008, 105:16695-16700.
25. Matsuse H., Kondo Y., Machida I., Kawano T., Saeki S., Tomari S., Obase Y., Fukushima C., Mizuta Y., Kohno S. Effects of anti-inflammatory therapies on recurrent and low-grade respiratory syncytial virus infections in a murine model of asthma. Ann Allergy Asthma Immunol 2006, 97:55-60.
26. Moos M.P., Mewburn J.D., Kan F.W., Ishii S., Abe M., Sakimura K., Noguchi K., Shimizu T., Funk C.D. Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J 2008, 22:4352-4362.
27. Ni N.C., Ballantyne L.L., Mewburn J.D., Funk C.D. Multiple-site activation of the cysteinyl leukotriene receptor 2 is required for exacerbation of ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2014, 34:321-330.
28. Ni N.C., Yan D., Ballantyne L.L., Barajas-Espinosa A., St Amand T., Pratt D.A., Funk C.D. A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J Pharmacol Exp Ther 2011, 339:768-778.
29. Nirogi R., Kandikere V., Mudigonda K., Bhyrapuneni G., Muddana N., Saralaya R., Benade V. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. J Neurosci Methods 2009, 178:116-119.
30. Nozaki M., Yoshikawa M., Ishitani K., Kobayashi H., Houkin K., Imai K., Ito Y., Muraki T. Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability. Keio J Med 2010, 59:10-18.
31. Parmentier C.N., Fuerst E., McDonald J., Bowen H., Lee T.H., Pease J.E., Woszczek G., Cousins D.J. Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. J Allergy Clin Immunol 2012, 129:1136-1142.
32. Pegg C.C., He C., Stroink A.R., Kattner K.A., Wang C.X. Technique for collection of cerebrospinal fluid from the cisterna magna in rat. J Neurosci Methods 2010, 187:8-12.
33. Pei L., Zhang Y., Chu X., Zhang J., Wang R., Liu M., Zhu X., Yu W. Peroxisome proliferator-activated receptor gamma promotes neuroprotection by modulating cyclin D1 expression after focal cerebral ischemia. Can J Physiol Pharmacol 2010, 88:716-723.
34. Schmued L.C., Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000, 874:123-130.
35. Sheng W.W., Li C.T., Zhang W.P., Yuan Y.M., Hu H., Fang S.H., Zhang L., Wei E.Q. Distinct roles of CysLT1 and CysLT2 receptors in oxygen glucose deprivation-induced PC12 cell death. Biochem Biophys Res Commun 2006, 346:19-25.
36. Shi Q.J., Xiao L., Zhao B., Zhang X.Y., Wang X.R., Xu D.M., Yu S.Y., Fang S.H., Lu Y.B., Zhang W.P., Sa X.Y., Wei E.Q. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res 2012.
37. Singh R.K., Gupta S., Dastidar S., Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010, 85:336-349.
38. Takahashi Y., Imai K., Ikeda H., Kubota Y., Yamazaki E., Susa F. Open study of pranlukast add-on therapy in intractable partial epilepsy. Brain Dev 2013, 35:236-244.
39. Terui T., Sano K., Okada M., Shirota H., Honda M., Ozawa M., Hirasawa N., Tamura G., Tagami H. Production and pharmacologic modulation of the granulocyte-associated allergic responses to ovalbumin in murine skin models induced by injecting ovalbumin-specific Th1 or Th2 cells. J Invest Dermatol 2001, 117:236-243.
40. Tohda Y., Nakahara H., Kubo H., Haraguchi R., Fukuoka M., Nakajima S. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999, 29:1532-1536.
41. Tureyen K., Vemuganti R., Sailor K.A., Dempsey R.J. Infarct volume quantification in mouse focal cerebral ischemia: a comparison of triphenyltetrazolium chloride and cresyl violet staining techniques. J Neurosci Methods 2004, 139:203-207.
42. Turner R.C., Dodson S.C., Rosen C.L., Huber J.D. The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. J Neurosurg 2013, 118:1072-1085.
43. Tuttolomondo A., Di Sciacca R., Di Raimondo D., Renda C., Pinto A., Licata G. Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr Top Med Chem 2009, 9:1240-1260.
44. Watters O., O'Connor J.J. A role for tumor necrosis factor-alpha in ischemia and ischemic preconditioning. J Neuroinflammation 2011, 8:87.
45. Wei E.Q., Zhu C.Y., Xu Q.Q., Yu Y.P., Zhu Y.F., Zheng M.Z. An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia. Sheng Li Xue Bao 2003, 55:742-747.
46. Wunder F., Tinel H., Kast R., Geerts A., Becker E.M., Kolkhof P., Hutter J., Erguden J., Harter M. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol 2010, 160:399-409.
47. Xing C., Arai K., Lo E.H., Hommel M. Pathophysiologic cascades in ischemic stroke. Int J Stroke 2012, 7:378-385.
48. Yamagami S., Tamura M., Hayashi M., Endo N., Tanabe H., Katsuura Y., Komoriya K. Differential production of MCP-1 and cytokine-induced neutrophil chemoattractant in the ischemic brain after transient focal ischemia in rats. J Leukoc Biol 1999, 65:744-749.
49. Yonemori F., Yamaguchi T., Yamada H., Tamura A. Evaluation of a motor deficit after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1998, 18:1099-1106.
50. Yu G.L., Wei E.Q., Wang M.L., Zhang W.P., Zhang S.H., Weng J.Q., Chu L.S., Fang S.H., Zhou Y., Chen Z., Zhang Q., Zhang L.H. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res 2005, 1053:116-125.
51. Yu G.L., Wei E.Q., Zhang S.H., Xu H.M., Chu L.S., Zhang W.P., Zhang Q., Chen Z., Mei R.H., Zhao M.H. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 2005, 73:31-40.
52. Zhang L.H., Wei E.Q. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacol Sin 2003, 24:1241-1247.
53. Zhang W.P., Hu H., Zhang L., Ding W., Yao H.T., Chen K.D., Sheng W.W., Chen Z., Wei E.Q. Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci Lett 2004, 363:247-251.
54. Zhang X.Y., Wang X.R., Xu D.M., Yu S.Y., Shi Q.J., Zhang L.H., Chen L., Fang S.H., Lu Y.B., Zhang W.P., Wei E.Q. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther 2013, 346:328-341.
55. Zhao B., Zhao C.Z., Zhang X.Y., Huang X.Q., Shi W.Z., Fang S.H., Lu Y.B., Zhang W.P., Xia Q., Wei E.Q. The new P2Y-like receptor G protein-coupled receptor 17 mediates acute neuronal injury and late microgliosis after focal cerebral ischemia in rats. Neuroscience 2012, 202:42-57.
56. Zhao C.Z., Zhao B., Zhang X.Y., Huang X.Q., Shi W.Z., Liu H.L., Fang S.H., Lu Y.B., Zhang W.P., Tang F.D., Wei E.Q. Cysteinyl leukotriene receptor 2 is spatiotemporally involved in neuron injury, astrocytosis and microgliosis after focal cerebral ischemia in rats. Neuroscience 2011, 189:1-11.
57. Zhao R., Shi W.Z., Zhang Y.M., Fang S.H., Wei E.Q. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol 2011, 63:550-557.
58. Zhou Y., Wei E.Q., Fang S.H., Chu L.S., Wang M.L., Zhang W.P., Yu G.L., Ye Y.L., Lin S.C., Chen Z. Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci 2006, 79:1645-1656.